Welcome to our dedicated page for West Pharm Svcs SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
West Pharmaceutical Services, Inc. filings document the regulatory record of a Pennsylvania operating company that supplies injectable drug containment, delivery and contract-manufacturing services. Its Form 8-K reports commonly furnish quarterly and full-year operating results, financial presentation materials and Regulation FD disclosures tied to earnings releases.
West's proxy and annual meeting filings cover board elections, executive compensation, advisory votes and shareholder voting results for its common stock. Other current reports record executive-transition matters and related governance disclosures, while exhibit filings provide the formal press releases, presentations and Inline XBRL cover-page data attached to those events.
West Pharmaceutical Services, Inc. filed an amended report updating details on a previously disclosed material cybersecurity attack. The company states that core enterprise systems are restored and that manufacturing, receiving and shipping processes have restarted at all sites, with global operations now fully functional.
The intrusion was initially detected on May 4, 2026, with data exfiltration and system encryption confirmed by May 7, 2026. The company reports no unauthorized activity or access has been observed since May 5, 2026. Based on its investigation to date, it believes the incident has not had, and is not reasonably likely to have, a material impact on its 2026 second-quarter and full-year financial guidance.
West Pharmaceutical Services senior vice president Shane Alden Campbell reported routine equity compensation activity involving restricted stock units that convert into common stock on a one-for-one basis. On May 12, 2026, he exercised 473.593 and 295.995 RSUs into common shares, while 134.927 and 84.329 shares were disposed of to cover tax liabilities. These transactions reflect derivative exercises and tax-withholding dispositions rather than open‑market buying or selling.
West Pharmaceutical Services, Inc. reported a material cybersecurity attack that involved data being exfiltrated by an unauthorized party and encryption of certain systems. After detecting the intrusion on May 4, 2026, the company took systems offline globally, notified law enforcement, and engaged external cyber‑forensic experts, including Palo Alto Networks’ Unit 42.
The attack and the company’s containment measures have temporarily disrupted business operations worldwide. Core enterprise systems have been restored and key shipping, receiving, and manufacturing processes have restarted at some sites, with other locations still being brought back online. The company has not yet determined the incident’s material impact on its financial condition or results.
WST notice of proposed sales of Common Stock tied to recent restricted stock vesting events. The filing lists planned dispositions associated with vesting on 04/23/2024, 05/06/2025, 05/07/2025, and 05/04/2026, showing individual lot sizes of 1, 430, 1, and 2,952 shares respectively.
Pucci Paolo reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Paolo Pucci received an equity grant in the form of restricted stock units. He was awarded 791 units of common stock on the reported date, increasing his direct holdings to 11,854.297 shares.
The footnote explains that these restricted stock units will vest in full on the date of the next annual shareholder meeting and will then be distributed under the company’s Deferred Compensation Plan for Outside Directors. This is a compensation-related award rather than an open-market purchase.
WEST PHARMACEUTICAL SERVICES INC director receives stock award. Director Douglas A. Michels acquired 791 shares of common stock as a grant or award, recorded at a price of $0.00 per share, reflecting equity compensation rather than a market purchase.
These shares are in the form of restricted stock units that will vest in full on the date of the next annual shareholder meeting and will be distributable under the company’s Deferred Compensation Plan for Outside Directors. After this grant, Michels directly holds 46,495.55 shares of common stock.
Lockhart Stephen H reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Stephen H. Lockhart received an equity award of 791 shares of common stock. The award is structured as restricted stock units that will vest in full on the date of the next annual shareholder meeting. After this grant, he holds a total of 3,523.2615 shares directly. This is a compensation-related grant, not an open-market purchase or sale.
LAI GOLDMAN MYLA reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Myla Lai-Goldman received 791 shares of Common Stock as a grant. The award was made at no cash cost per share and increased her directly held position to 20,434.587 shares.
According to the footnote, these shares are in the form of restricted stock units that will vest in full on the date of the next annual shareholder meeting and will be distributed under the company’s Deferred Compensation Plan for Outside Directors.
Keller Deborah L reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Deborah L. Keller received a grant of 791 shares of common stock in the form of restricted stock units on May 4, 2026. These restricted stock units will vest in full on the date of the next annual shareholder meeting. After this award, she directly holds 11,560.479 shares of West Pharmaceutical Services common stock.
Joseph Molly reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Molly Joseph received a grant of 791 shares of common stock as restricted stock units. The award was granted at a price of $0.00 per share, reflecting equity compensation rather than an open-market purchase. After this grant, Joseph holds a total of 4,398.187 shares of West Pharmaceutical common stock. According to the disclosure, these restricted stock units will vest in full on the date of the next annual shareholder meeting, at which point they are expected to become fully owned shares, subject to any applicable plan terms.